Ianalumab plus eltrombopag for pediatric ITP after steroid failure
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study tests a new combination of two medicines (ianalumab and eltrombopag) for children with a blood condition called ITP (low platelets causing bruising and bleeding) who haven't improved with steroids. The goal is to see if this combination can safely raise platelet counts and reduce bleeding risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Aged 5 to under 18 years
- Diagnosis of primary ITP that did not improve or came back after steroids (with or without IVIG treatment)
- Low platelet count (below 30) and eligible to take eltrombopag
- Up-to-date on childhood vaccinations per local schedule
- No prior second-line treatments for ITP (except short-term TPO-RAs for up to one week)
- No other blood disorders, severe infections, liver or kidney problems, or bleeding issues
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two treatment approaches for adults with primary immune thrombocytopenia (ITP), a condition where platelet counts are too low. It looks at whether adding rituximab to eltrombopag helps control ITP better and more safely.
This study tests a sequence of two medicines that help raise platelet counts in people with severe ITP. The first is given as an injection, and the second is a pill, and they are given after standard steroid treatment. The goal is to see if this approach can improve platelet levels safely.
This trial compares two ways to raise platelet counts in people with immune thrombocytopenia (ITP) who did not get enough benefit from a short course of a standard medicine. One option is a higher dose of a similar medicine, and the other is switching to a different pill. The goal is to find a treatment that works better with fewer side effects.
This trial tests a new drug called ianalumab combined with a standard platelet-boosting medicine (TPO-RA) for adults with immune thrombocytopenia (ITP) or Evans syndrome. The goal is to see if the combination is well-tolerated and helps raise platelet counts.
This study tests a new combination of two medicines—one that calms the immune system and one that helps your body make more platelets. It is for people with long-term ITP who have already tried other treatments and still have low platelet counts.
This study tests whether adding another medicine (telitacicept) to a standard platelet-boosting drug (eltrombopag) works better than eltrombopag alone for adults with ITP that hasn't improved with steroids. The goal is to help raise your platelet counts and reduce bleeding risk.
Hear when a new Primary Immune Thrombocytopenia (ITP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.